A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

What this Trial Is About

Researchers are evaluating whether patients with symptomatic myeloma can safely self-administer the chemotherapy drug bortezomib at home using subcutaneous injections. This study challenges the traditional hospital-based chemotherapy delivery model by assessing if home administration, performed by the patient or caregiver, can be effective and safe. The study is phase 2 and sponsored by AHS Cancer Control Alberta, addressing concerns about system capacity and patient time commitments. Participants will learn to give themselves subcutaneous injections of bortezomib at home after having received at least four prior doses in a hospital or cancer center. The study does not use a placebo or comparison group and is not blinded. All tests and assessments follow standard care procedures, focusing on self-administration in a home environment. During the study, researchers will monitor how many patients can self-administer successfully, myeloma response, adverse events of grade 3 or higher, missed doses, and patient satisfaction through surveys. The study duration is two years from enrollment start, with regular evaluations based on standard care. Safety and quality of life are key measures, with close monitoring to ensure participants’ wellbeing throughout.

A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment